News
Apollo, Nimbus lead bumper week for biotech financings
This week saw a series of big-ticket funding rounds for biotech …
19812 items found
News
CSL, BrightInsight launch Hemgenix companion app
CSL Behring's recently approved gene therapy for haemophilia B …
News
NICE changes its mind on Lilly's Mounjaro for diabetes
Around 180,000 people with type 2 diabetes in the UK could be in line …
News
Seagen partners Nurix on 'degrader-antibody conjugates'
Seagen hasn't let a pending acquisition by Pfizer interrupt its …
Oncology
Combining new and existing immunity: A 3D approach to killing cancer
A question which has long baffled scientists, frustrated clinicians, …
News
Lift for Roche as Alnylam drug lowers blood pressure
Just weeks after wagering $310 million upfront on the rights to …
R&D
Partner Content
Advanced Purification for Complex Biologics Summit
The Advanced Purification for Complex Biologics Summit is the first …
Sales & Marketing
Deep Dive: Communications & Commercialisation 2023
The battle over drug pricing reforms in the US is heading for the …
Oncology
Five takeaways from the CAR-TCR cell therapy conference
Last week, I had the privilege of heading into town in Boston to …
News
Inceptive raises $100m, plus other digital financings
Our latest round-up of financings in the digital health category is …
News
Grogan named Biogen research chief as reset continues
Chris Viehbacher's efforts to reinvigorate Biogen are continuing to …
R&D
The importance of collaboration in tackling the ethical concerns of cell and gene therapy
Cell and gene therapies (CGT) offer immense potential for healthcare …
News
Sarepta pulls plug on Duchenne exon-skipping drug
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Patients
Deep Dive: Patients & Partnerships 2024
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
From neurosurgery to focused ultrasound: Not if, but when
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Welcome to the Molecular Glue Drug Development Summit!
The Molecular Glue Drug Development Summit is back in January, 2025!
R&D
Partner Content
Welcome to the 6th RNAi-Based Therapeutics Summit!
RNAi-Based Therapeutics Returns!
